Anti-SARS-Cov-2 antibodies derived from 2GHW
US11021531B1 · kind B1 · utility
7Cited by
0References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 14, 2020 |
| Grant date | Jun 1, 2021 |
| Priority date | — |
| Expiry date | May 14, 2040 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/92
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
This disclosure provides antibodies and antigen-binding fragments that are derived from 2ghw and that can be administered to an individual that is infected or suspected of being infected with a virus. Antibodies and antigen-binding fragments provided herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies and antigen-binding fragments provided herein can be used to diagnose a SARS-Cov-2 infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.